MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

185 / 348 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 17:04 UTC

Suurimad hinnamuutused turgudel

FDA Rejects Replimune's Melanoma Drug for a Second Time

11. apr 2026, 00:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Big Yachts, Big Bucks -- Barrons.com

10. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. apr 2026, 21:01 UTC

Tulu

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10. apr 2026, 18:25 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Finish With Weekly Gains -- Market Talk

10. apr 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10. apr 2026, 17:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10. apr 2026, 17:26 UTC

Tulu

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10. apr 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10. apr 2026, 17:00 UTC

Uudisväärsed sündmused

Construction Business Taking a Hit From Iran Conflict -- WSJ

10. apr 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10. apr 2026, 16:12 UTC

Tulu

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10. apr 2026, 16:11 UTC

Tulu

Partners Group: Traditional Programs Contributed $3.3B

10. apr 2026, 16:10 UTC

Tulu

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10. apr 2026, 16:10 UTC

Tulu

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10. apr 2026, 16:10 UTC

Tulu

Partners Group 1Q New Client Demand $8.3B

10. apr 2026, 16:09 UTC

Tulu

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10. apr 2026, 15:54 UTC

Omandamised, ülevõtmised, äriostud

Plenitude Completes Acquisition of Acea Energia

10. apr 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

185 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.